A Study of Cells in the Blood that may be Contributing to Allergic Inflammation in Asthmatics
Overview
Tab Title Description
Study type
ObservationalDescribes the nature of a clinical study. Types include:
- Observational study — observes people and measures outcomes without affecting results.
- Interventional study (clinical trial) — studies new tests, treatments, drugs, surgical procedures or devices.
- Medical records research — uses historical information collected from medical records of large groups of people to study how diseases progress and which treatments and surgeries work best.
Study IDs
Site IRB
- Rochester, Minnesota: 13-004773
Sponsor Protocol Number: 13-004773
About this study
The purpose of this study is to identify a new population of cells in the blood that may be contributing to allergic inflammation in atopic asthmatics.
Participation eligibility
Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.
Inclusion Criteria:
Normal Healthy Individuals
- Healthy individuals with no history of asthma or allergy
- Normal spirometry
- Normal exhaled nitric oxide (eNO) test
- Blood eosinophils < 0.5 x 10 9 cells / L
- Negative skin prick test results or negative IgE serum tests to 10 common aeroallergens
Patients with Asthma with and without Nasal Polyps
- Asthma patients from the clinical practice of the Division of Allergic Diseases, Mayo Clinic Rochester
- The definition of asthma is based on the National Asthma Education and Prevention Program (NAEPP) 2007 Expert Panel Report
- Includes a physician’s determination that the subject’s history and physical examination are consistent with the diagnosis.
- Asthma patients have a history of variable airflow obstruction with at least 1 of the following:
- Airway hyperreactivity (AHR)(PC20 methacholine ≤16 mg/ml) OR
- A positive bronchodilator response (FEV1 change ≥12% following 2 puffs of albuterol (90 µg per puff) documented within the past 2 years.
Exclusion Criteria:
- Received systemic glucocorticoids during the past 3 months
- Previous (> 10 pack year smoking history) or current smokers
- Lower or upper airway infection (eg. “cold”) in the last 4 weeks
- Diagnosed with immunodeficiency, cystic fibrosis, or any other respiratory or general medical problem which in the investigator feels would preclude inclusion into the study e.g. infection, malignancy
- Immunotherapy with any allergen
- Pregnancy
- Immunosuppressive medication
Participating Mayo Clinic locations
Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.
| Mayo Clinic Location |
Status |
|
Rochester, Minn.
Mayo Clinic principal investigator Hirohito Kita, M.D. |
Closed for enrollment |
|
More information
Publications
Publications are currently not available